GUIDI, LORENZO
GUIDI, LORENZO
Universita' degli Studi di MILANO
Extendeond Endocrine Therapy and Survival for Breast Cancer Subtypes in Premenopausal Patients
2026 C. Valenza, Y. Zheng, M. Milano, P.P.M. Berton Giachetti, D. Trapani, E. Giordano, L. Guidi, L. Boldrini, G. Castellano, J. Katrini, B. Malagutti, G. Antonarelli, J.D. Etessami, N. Bianco, F. Conforti, G.J. Kirkner, C. Sangalli, K.E. Dibble, N. Fusco, M. Colleoni, M.M. Regan, E. Munzone, G. Curigliano, A.H. Partridge
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort Study
2026 C. Valenza, Y. Zheng, M. Milano, D. Trapani, E. Giordano, L. Guidi, P.P.M. Berton Giachetti, L. Boldrini, G. Castellano, J. Katrini, B. Malagutti, G. Antonarelli, F. Conforti, E. Pagan, V. Bagnardi, G.J. Kirkner, C. Sangalli, K.E. Dibble, M. Colleoni, M.M. Regan, E. Munzone, G. Curigliano, A.H. Partridge
Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances
2025 L. Guidi, J. Etessami, C. Valenza, A. Valdivia, F. Meric-Bernstam, E. Felip, G. Curigliano
Targeting androgen receptors in patients with metastatic breast cancer
2025 L. Guidi, D. Trapani, G. Curigliano
An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer
2025 R. Asnaghi, G. Antonarelli, E. Battaiotto, G. Castellano, L. Guidi, D. Izzo, P. Zagami, D. Trapani, G. Curigliano
Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study
2025 C. Valenza, M. Mongillo, M.V. Visconti, J. Katrini, D. Trapani, L. Boldrini, L. Guidi, A. Farfalla, D. Malengo, G. Caruso, S. Derio, M. Lapresa, G. Parma, E. Biagioli, E. Omodeo Salé, G. Curigliano, N. Colombo
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study
2025 C. Valenza, E. Nicolò, M. Mongillo, D. Trapani, J. Katrini, L. Boldrini, L. Boscolo Bielo, G. Castellano, L. Guidi, G. Pellizzari, J. Villa, S. Derio, M. Lapresa, F. Gigli, G. Parma, E. Omodeo Salè, E. Derenzini, G. Curigliano, N. Colombo
Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy
2025 D. Izzo, L. Ascione, L. Guidi, R.M. Marsicano, C. Koukoutzeli, D. Trapani, G. Curigliano
The Effect of Thermal Processes on the Organoleptic and Nutraceutical Quality of Tomato Fruit (Solanum lycopersicum L.)
2024 F. Narra, F.I. Brigante, E. Piragine, P. Solovyev, G. Benedetti, F. Araniti, L. Bontempo, C. Ceccanti, A. Martelli, L. Guidi
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
2024 L. Cantini, D. Trapani, L. Guidi, L. Boscolo Bielo, R. Scafetta, M. Koziej, L. Vidal, K.S. Saini, G. Curigliano
Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates
2024 L. Ascione, L. Guidi, A. Prakash, D. Trapani, P. Lorusso, E. Lou, G. Curigliano
Unfavorable carcinoma of unknown primary with a gastrointestinal profile: a retrospective study
2024 L. Guidi, C. Valenza, E. Battaiotto, D. Trapani, M.C. Ghioni, E. Crimini, L. Boscolo Bielo, K. Venetis, C. Belli, L. Bottiglieri, L. Gervaso, C.A. Cella, D. Ciardiello, F. Spada, L. Benini, R. Adorisio, E. Mane, N. Fazio, E. Guerini Rocco, G. Curigliano, M.G. Zampino
Antibody-drug conjugates in metastatic breast cancer: Sequencing, combinations and resistances
2024 L. Guidi, L. Boldrini, D. Trapani, G. Curigliano
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study
2024 C. Valenza, D. Trapani, P. Zagami, G. Antonarelli, L. Boscolo Bielo, E. Nicolò, J.M. Ribeiro, L. Guidi, C. Reduzzi, M. Spotti, L. Adamoli, J. Cortès, B. Pistilli, S.M. Tolaney, N. Ueno, R.M. Layman, M. Cristofanilli, L.A. Carey, E. Munzone, C. Criscitiello, F. Lynce, W.A. Woodward, G. Curigliano
Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms
2024 C. Valenza, M. Mongillo, F. Gigli, D. Trapani, J. Katrini, E. Nicolò, L. Boldrini, L. Boscolo Bielo, G. Castellano, L. Guidi, G. Pellizzari, S. Derio, M. Lapresa, G. Parma, E. Derenzini, G. Curigliano, N. Colombo
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer
2024 L. Boscolo Bielo, D. Trapani, E. Nicolò, C. Valenza, L. Guidi, C. Belli, E. Kotteas, A. Marra, A. Prat, N. Fusco, C. Criscitiello, H.J. Burstein, G. Curigliano
Circulating tumor DNA in patients with locally advanced rectal cancer treated with multimodal treatment
2024 L. Gervaso, D. Ciardiello, G. Gregato, L. Guidi, C. Valenza, L. Ascione, L. Boldrini, S. Frassoni, C.A. Cella, F. Spada, L. Funicelli, G. De Roberto, W. Petz, S. Borin, M.A. Gerardi, L. Bottiglieri, D. Tamayo, E. Bertani, U. Fumagalli Romario, V. Bagnardi, G. Curigliano, F. Bertolini, N. Fazio, M.G. Zampino
Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study
2024 D. Trapani, R. Scalia, E. Giordano, G. Castellano, G. Doi, A. Gaeta, G. Pellizzari, A. Carnevale Schianca, J. Katrini, S. D'Ambrosio, C. Santoro, L. Guidi, C. Valenza, C. Belli, S. Gandini, A. Russo, G. Curigliano
Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges
2023 L. Guidi, G. Pellizzari, P. Tarantino, C. Valenza, G. Curigliano
Antibody–drug conjugates targeting HER2-mutant or HER2-(non) amplified solid tumors: is HER2 an agnostic target?
2023 L. Guidi, C. Valenza, D. Trapani, G. Curigliano